Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 87 articles: HTML format

Single Articles

April 2026
1. DERANGERE V, Lecuelle J, Lepage C, Salem OA, et al
   Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].
   Eur J Cancer. 2026;239:116586.
   PubMed    
   
   
   
2. AMBROSINI M, Gallois C, Gandini A, Lecanu A, et al
   From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.
   Eur J Cancer. 2026;239:116731.
   PubMed     Abstract available
   
   
   March 2026
3. FOURNIER E, Schaffar R, Staehelin K, Rouxel N, et al
   Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021.
   Eur J Cancer. 2026;239:116707.
   PubMed     Abstract available
   
   
   
4. HOFHEINZ RD, Weikersthal LFV, Dechow T, Depenbusch R, et al
   Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).
   Eur J Cancer. 2026;239:116689.
   PubMed     Abstract available
   
   
   
5. WAGNER AD, Raeisi M, Rakez M, Diasio RD, et al
   Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
   Eur J Cancer. 2026;238:116694.
   PubMed     Abstract available
   
   
   
6. KITO Y, Yamazaki K, Shoji H, Yamada T, et al
   Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
   Eur J Cancer. 2026;238:116688.
   PubMed     Abstract available
   
   
   
7. AL-TOMA D, Kemna R, Ali M, Zwart K, et al
   Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial.
   Eur J Cancer. 2026;238:116668.
   PubMed     Abstract available
   
   
   February 2026
8. GHEDRI A, van der Baan FH, Otten JMMB, Elferink MAG, et al
   Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study.
   Eur J Cancer. 2026;237:116588.
   PubMed     Abstract available
   
   
   
9. MAERTEN P, Defraene G, Wolthuis A, Schraepen C, et al
   Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world data.
   Eur J Cancer. 2026;234:116199.
   PubMed     Abstract available
   
   
   
10. ZHANG X, Zhou J, Geng J, Li Y, et al
    Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial.
    Eur J Cancer. 2026;234:116193.
    PubMed     Abstract available
    
    
    
11. FRANKEN IA, Ketelaars SLC, Rubio-Alarcon C, Delis-van Diemen P, et al
    Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.
    Eur J Cancer. 2026;236:116262.
    PubMed     Abstract available
    
    
    January 2026
12. DARAI A, de Vries S, Beets GL, Nagtegaal ID, et al
    Trends in organ preservation in rectal cancer management: A population-based study in the Netherlands.
    Eur J Cancer. 2026;232:116154.
    PubMed     Abstract available
    
    
    
13. LUNENBERG RA, Franken IA, Braat MNGJA, Elferink MAG, et al
    The impact of mismatch repair status on accuracy of clinical staging in stage II/III rectal cancer in daily practice.
    Eur J Cancer. 2026;232:116117.
    PubMed     Abstract available
    
    
    December 2025
14. WERF-'T LAM AV, Dowty JG, Italia M, Bakker AC, et al
    Cancer risks for MSH6 pathogenic variant carriers.
    Eur J Cancer. 2025;231:116098.
    PubMed     Abstract available
    
    
    
15. VANDE KERCKHOVE FEC, van den Berg K, van Erning FN, Daniels-Gooszen AW, et al
    Implications of inaccurate lymph node staging in early and intermediate-risk rectal cancer on survival-related outcomes in a large Dutch population-based cohort.
    Eur J Cancer. 2025;231:116052.
    PubMed     Abstract available
    
    
    November 2025
16. HEINRICH K, Stintzing S, Weikersthal LFV, Decker T, et al
    Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
    Eur J Cancer. 2025;232:116133.
    PubMed     Abstract available
    
    
    
17. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    PubMed     Abstract available
    
    
    
18. CERVANTES B, Grosnon C, Samaille T, Mas L, et al
    Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management.
    Eur J Cancer. 2025;232:116119.
    PubMed     Abstract available
    
    
    
19. WEISS L, Stintzing S, Modest DP, Stahler A, et al
    First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (
    Eur J Cancer. 2025;232:116105.
    PubMed     Abstract available
    
    
    
20. MIRANDOLA A, Cartry J, Bedja S, Pisareva E, et al
    Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients.
    Eur J Cancer. 2025;231:116097.
    PubMed     Abstract available
    
    
    
21. BREGNI G, Leurquin B, Giasafaki P, Takemura N, et al
    Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis.
    Eur J Cancer. 2025;231:116092.
    PubMed     Abstract available
    
    
    October 2025
22. KIM Y, Kim EY, Kim MY, Cho BH, et al
    Immune-enhanced machine learning approach for early detection of precancerous colorectal neoplasia: Insights from biomarkers in routine health checkups.
    Eur J Cancer. 2025;229:115786.
    PubMed     Abstract available
    
    
    
23. YAMAMOTO K, Bando H, Misumi T, Nishikawa T, et al
    Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    Eur J Cancer. 2025;230:116034.
    PubMed     Abstract available
    
    
    September 2025
24. BERGEN ES, Le Malicot K, Taieb J
    Response to letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115798.
    PubMed    
    
    
    
25. LIU J, Yang S, Zhang G
    Letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115797.
    PubMed    
    
    
    
26. ONDER AH, Catli MM
    Colorectal cancer treatment commentary review.
    Eur J Cancer. 2025;230:115809.
    PubMed     Abstract available
    
    
    
27. BATTAGLIN F, O'Neil BH, Stintzing S, Ou FS, et al
    Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
    Eur J Cancer. 2025;227:115694.
    PubMed     Abstract available
    
    
    
28. DASARI A, Eng C, Lonardi S, Garcia-Carbonero R, et al
    Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
    Eur J Cancer. 2025;227:115641.
    PubMed     Abstract available
    
    
    
29. LANGHEINRICH M, Gerken M, Robers G, Hansinger J, et al
    Survival benefit of adjuvant chemotherapy in elderly patients with UICC stage III colon carcinoma: A 20-year population-based German cohort study.
    Eur J Cancer. 2025;227:115583.
    PubMed     Abstract available
    
    
    August 2025
30. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    PubMed     Abstract available
    
    
    
31. HAN L, Josephs D, McDonald L, Gomm L, et al
    The effect of centralising novel cell therapies for solid cancers - a health systems planning model for Europe.
    Eur J Cancer. 2025;226:115594.
    PubMed     Abstract available
    
    
    
32. MICHIEL ZEEUW J, Kemna R, Ali M, van Eck S, et al
    Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.
    Eur J Cancer. 2025;228:115738.
    PubMed     Abstract available
    
    
    
33. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    PubMed     Abstract available
    
    
    
34. ANTONIOTTI C, Marmorino F, Rossini D, Schmoll HJ, et al
    FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
    Eur J Cancer. 2025;228:115713.
    PubMed     Abstract available
    
    
    July 2025
35. CIARDIELLO D, Boscolo Bielo L, Napolitano S, Cioli E, et al
    Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.
    Eur J Cancer. 2025;226:115642.
    PubMed     Abstract available
    
    
    
36. TAIEB J, Modest DP, Fakih M, Ciardiello F, et al
    Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
    Eur J Cancer. 2025;227:115644.
    PubMed     Abstract available
    
    
    
37. GALLOIS C, Ambrosini M, Lonardi S, Alouani E, et al
    Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Eur J Cancer. 2025;227:115645.
    PubMed     Abstract available
    
    
    
38. BERGEN ES, Canton C, Boulin M, Le Malicot K, et al
    Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;227:115643.
    PubMed     Abstract available
    
    
    
39. VAN DRIEL MHE, Wullaert L, Voigt KR, Outmani L, et al
    Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study.
    Eur J Cancer. 2025;226:115599.
    PubMed     Abstract available
    
    
    June 2025
40. LIU R, Yin X, Bai Y, Zhong H, et al
    A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
    Eur J Cancer. 2025;226:115566.
    PubMed     Abstract available
    
    
    
41. SHAMSEDDINE A, Turfa R, Chehade L, Zeidan YH, et al
    Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study.
    Eur J Cancer. 2025;222:115428.
    PubMed     Abstract available
    
    
    May 2025
42. HAFLIGER E, Nili-Asgari R, Netter J, Taieb J, et al
    Case report of two fatal cerebral hemorrhages in patients with metastatic colorectal cancer treated with Fruquintinib.
    Eur J Cancer. 2025 May 19:115517. doi: 10.1016/j.ejca.2025.115517.
    PubMed    
    
    
    April 2025
43. MORETTO R, Rossini D, Polito MG, Antoniotti C, et al
    The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
    Eur J Cancer. 2025;222:115470.
    PubMed     Abstract available
    
    
    
44. PIZZAMIGLIO M, Soulabaille A, Lahlou W, Pilla L, et al
    Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.
    Eur J Cancer. 2025;222:115471.
    PubMed     Abstract available
    
    
    
45. NORONHA MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, et al
    Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials.
    Eur J Cancer. 2025;222:115476.
    PubMed     Abstract available
    
    
    
46. JORGENSEN SF, Njor SH, Nevala A, Palsson B, et al
    Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators.
    Eur J Cancer. 2025;222:115444.
    PubMed     Abstract available
    
    
    
47. WEISS L, Stintzing S, Stahler A, Benedikt Westphalen C, et al
    Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2025;221:115399.
    PubMed     Abstract available
    
    
    March 2025
48. HOLCH JW, Ohnmacht AJ, Stintzing S, Heinrich K, et al
    FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
    Eur J Cancer. 2025;220:115388.
    PubMed     Abstract available
    
    
    
49. MORETTO R, Boccaccio C, Landi M, Masi G, et al
    Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorit
    Eur J Cancer. 2025;218:115261.
    PubMed     Abstract available
    
    
    
50. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    PubMed     Abstract available
    
    
    February 2025
51. POUMEAUD F, Valentin T, Fares N, Segier B, et al
    Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
    Eur J Cancer. 2025;216:115196.
    PubMed     Abstract available
    
    
    
52. QIU X, Zhou J, Qiu H, Shen Z, et al
    A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R.
    Eur J Cancer. 2025;216:115156.
    PubMed     Abstract available
    
    
    January 2025
53. SOBRERO A, Dasari A, Aquino J, Lonardi S, et al
    Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
    Eur J Cancer. 2025;218:115268.
    PubMed     Abstract available
    
    
    
54. WANG DS, Pat Fong W, Wen L, Cai YY, et al
    Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
    Eur J Cancer. 2025;214:115154.
    PubMed     Abstract available
    
    
    December 2024
55. CARBONE F, Spinelli A, Ciardiello D, Realis Luc M, et al
    Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
    Eur J Cancer. 2024;215:115172.
    PubMed     Abstract available
    
    
    
56. TOUGERON D, Bibeau F, Chibaudel B, Kim S, et al
    Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Eur J Cancer. 2024;213:115082.
    PubMed     Abstract available
    
    
    November 2024
57. HIRANO H, Kataoka K, Yamaguchi T, Wagner AD, et al
    Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
    Eur J Cancer. 2024;214:115139.
    PubMed     Abstract available
    
    
    
58. DUNN C, Shapiro J, Lee M, Wong R, et al
    Measuring quality in the care of metastatic colorectal cancer utilising available registry data: A modified Delphi study.
    Eur J Cancer. 2024;214:115142.
    PubMed     Abstract available
    
    
    
59. XIAO A, Li X, Wang C, Ye J, et al
    Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
    Eur J Cancer. 2024;213:115111.
    PubMed     Abstract available
    
    
    
60. SUN L, Xu Y, Chen N, Zhang C, et al
    Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.
    Eur J Cancer. 2024;213:115109.
    PubMed     Abstract available
    
    
    
61. FRYDENDAHL A, Nors J, Rasmussen MH, Henriksen TV, et al
    Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.
    Eur J Cancer. 2024;211:114314.
    PubMed     Abstract available
    
    
    October 2024
62. STINTZING S, Yoshino T
    Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;210:114298.
    PubMed    
    
    
    
63. FOKAS E, Williams H, Diefenhardt M, Lin S, et al
    Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
    Eur J Cancer. 2024;210:114291.
    PubMed     Abstract available
    
    
    September 2024
64. SMABERS LP, Huismans MA, van Nieuwenhuijzen N, Minnema MC, et al
    Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.
    Eur J Cancer. 2024;212:115059.
    PubMed     Abstract available
    
    
    
65. MARGALIT O, Stemmer A, Chapin WJ, Shacham-Shmueli E, et al
    Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
    Eur J Cancer. 2024;212:114336.
    PubMed     Abstract available
    
    
    
66. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    PubMed     Abstract available
    
    
    August 2024
67. AMBROSINI M, Tougeron D, Modest D, Guimbaud R, et al
    BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
    Eur J Cancer. 2024;210:114290.
    PubMed     Abstract available
    
    
    
68. XIE Z, Lin H, Huang Y, Wang X, et al
    BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer.
    Eur J Cancer. 2024;210:114278.
    PubMed     Abstract available
    
    
    
69. ZHANG P, Han Y, Cai Z, Cao D, et al
    Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024 Aug 6:114266. doi: 10.1016/j.ejca.2024.114266.
    PubMed    
    
    
    
70. MICHIEL ZEEUW J, Wesdorp NJ, Ali M, Bakker AJJ, et al
    Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.
    Eur J Cancer. 2024;207:114185.
    PubMed     Abstract available
    
    
    July 2024
71. FRANKEN IA, van der Baan FH, Vink GR, May AM, et al
    Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months.
    Eur J Cancer. 2024;208:114207.
    PubMed     Abstract available
    
    
    June 2024
72. MERCIER L, Delaye M, Fuerea A, Ducreux M, et al
    Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.
    Eur J Cancer. 2024;208:114193.
    PubMed    
    
    
    
73. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    PubMed     Abstract available
    
    
    
74. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Corrigendum to "Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021'' Volume 205, July 2024, 114104.
    Eur J Cancer. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155.
    PubMed    
    
    
    
75. COHEN R, Raeisi M, Chibaudel B, Shi Q, et al
    Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Eur J Cancer. 2024;207:114160.
    PubMed     Abstract available
    
    
    
76. ZWART WH, Temmink SJD, Hospers GAP, Marijnen CAM, et al
    Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.
    Eur J Cancer. 2024;204:114044.
    PubMed     Abstract available
    
    
    May 2024
77. CHEN C, Feng YS, Wang Z, Gupta M, et al
    Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer.
    Eur J Cancer. 2024;207:114147.
    PubMed     Abstract available
    
    
    
78. TAIEB J, Basile D, Seligmann J, Argiles G, et al
    Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
    Eur J Cancer. 2024;206:114118.
    PubMed     Abstract available
    
    
    
79. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021.
    Eur J Cancer. 2024;205:114104.
    PubMed     Abstract available
    
    
    
80. MOREAU M, Alouani E, Flecchia C, Falcoz A, et al
    A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Eur J Cancer. 2024;202:114033.
    PubMed     Abstract available
    
    
    
81. VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al
    Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
    Eur J Cancer. 2024;202:114021.
    PubMed     Abstract available
    
    
    March 2024
82. TAKASHIMA A, Garcia-Alfonso P, Manneh R, Besen AA, et al
    Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Eur J Cancer. 2024;205:114036.
    PubMed     Abstract available
    
    
    
83. BARBE R, Belkouchi Y, Menu Y, Cohen R, et al
    Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
    Eur J Cancer. 2024;202:114020.
    PubMed     Abstract available
    
    
    
84. SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al
    Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Eur J Cancer. 2024;202:113988.
    PubMed     Abstract available
    
    
    
85. LI L
    Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
    Eur J Cancer. 2024;202:113982.
    PubMed    
    
    
    
86. YOSHINO T, Hooda N, Younan D, Muro K, et al
    A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;202:113975.
    PubMed     Abstract available
    
    
    November 2023
87. SHKURTI J, van den Berg K, van Erning FN, Lahaye MJ, et al
    Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands.
    Eur J Cancer. 2023;193:113314.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum